Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V Agreement Appears Set Between FDA And Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

Final package expected to be published in late summer following clearance by the administration.

You may also be interested in...



Biosimilar User Fee Negotiations Won't Start Until 2016

Mid-December kick-off meeting puts emerging user fee program on much later track than others.

Clinical Reviewers To CDER: Give Us PRO Training

A repository of patient-reported outcomes instruments and dedicated PRO experts in each review division also could help boost the use of such data in drug labeling, FDA reviewers said.

ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics

One project will look at tablet size, odor and other characteristics that in the past have been a source of public complaints about generics.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel